Kuros Biosciences (CHIX:KURNZ) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 27, 2026)


CHIX:KURNZ Kuros Biosciences Ltd CHIX:KURNZ
70 GF Score
Price CHF18.29
GF Value CHF38.68
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Kuros Biosciences Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Kuros Biosciences's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

CHIX:KURNZ vs ABT, SYK, MDT: Margin of Safety % (DCF Earnings Based) Comparison

For the Medical Devices subindustry, Kuros Biosciences's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kuros Biosciences Margin of Safety % (DCF Earnings Based) vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Kuros Biosciences's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Kuros Biosciences's Margin of Safety % (DCF Earnings Based) falls into.


CHIX:KURNZ
70GF Score
Kuros Biosciences Ltd CHIX:KURNZ
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Kuros Biosciences (CHIX:KURNZ) Overvalued in 2026?

Based on GuruFocus' analysis, Kuros Biosciences stock appears to be undervalued. The current stock price of CHF18.29 is trading 52.7% below its estimated GF Value™ of CHF38.68. GuruFocus considers Kuros Biosciences to be Significantly Undervalued.

Key valuation signals for CHIX:KURNZ:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: CHF38.68 vs. price of CHF18.29 (52.7% below fair value)
  • GF Score™: 70/100 with 2 warning signs

No single metric tells the full story. See the CHIX:KURNZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kuros Biosciences Business Description

Address Wagistrasse 25, Schlieren, Zurich, CHE, 8952
Kuros Biosciences Ltd is a Swiss-based biotech company, focused on developing and commercializing biologic bone graft technologies for musculoskeletal applications, particularly in spine, trauma, extremities, and oncology. It has two reportable segments: i) Medical Devices: This segment includes products such as MagnetOs and Attrax, which are biphasic calcium phosphate (BCP) bone grafts that mimic the porous, trabecular structure of cancellous bone. ii) Legacy Portfolio: This segment includes all non-core products (including Checkmate licensing) that are outside the Group's primary therapeutic focus. The majority of the company's revenue is derived from the Medical Devices segment. Geographically, it generates the maximum revenue from the United States of America.
70GF Score

Get the complete analysis for CHIX:KURNZ

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF18.29
Price
CHF38.68
GF Value